Carbios reduces operating charges by 19% in first half 2026 and maintains €48 million in cash reserves
Carbios published its first half 2026 results on September 24, 2026, marked by the continuation of its cost control plan.
The biotechnology company based in Clermont-Ferrand reduced its operating charges by 19% year-on-year, while making progress on the financing of its Longlaville plant and on its commercial agreements.
Operating loss reduced by €3.9 million over one year
In the first half of 2026, Carbios' operating charges decreased by €3.4 million, representing a 19% decline compared to the first half of 2025. They stood at €14.4 million, against €17.8 million a year earlier, according to Carbios SA's income statement.
Operating loss was €11.8 million, an improvement of €3.9 million year-on-year. Net loss reached €9.4 million, compared to €11.9 million in the first half of 2025, a reduction of €2.5 million.
Carbios SA's operating revenues amounted to €2.6 million, against €2.1 million a year earlier.
Reduced cash consumption and position of €48 million
Carbios SA's net cash consumption was limited to €4.2 million in the first half of 2026, compared to €33.4 million over the same period in 2025. This change reflects the decline in operating expenses (€8.3 million in savings) and investments (nearly €14 million).
Carbios SA also received a partial repayment of €8 million in respect of the shareholder loan granted to its subsidiary Carbios 54. At the group level, cash consumption amounted to €11 million, compared to €18 million a year earlier.
The company reports having a cash position of €48 million as of June 30, 2026, enabling it to cover its operating charges beyond the next twelve months. For the second half of 2026, Carbios intends to continue its cost control efforts.
Longlaville financing: banking approvals and ongoing commercial agreement
Carbios obtained approval from the credit committees of the majority of the lenders of the Longlaville project during the summer. Independent reviews covering technical, economic, environmental and legal aspects confirmed the economic viability of the project and the relevance of its location in France.
A commercial agreement is being finalized with a player in the beverage sector, which should bring the plant's pre-sales level to 60% of its nominal capacity. Due diligences conducted by export credit agencies (Bpifrance Assurance Export and EIFO) and capital partners remain ongoing.
The company also continued the implementation of the strategic partnership signed with Wankai New Materials on December 2, 2025, through the creation of the joint venture Kaibio Biotechnology Co. Ltd. The 2026 semi-annual financial report will be made available on the company's website by September 30, 2026 at the latest.
